🇺🇸 FDA
Patent

US 12239729

TRPV3 agonists for the treatment of skin conditions

granted A61KA61K38/08A61K38/10

Quick answer

US patent 12239729 (TRPV3 agonists for the treatment of skin conditions) held by Soricimed Biopharma Inc. expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Soricimed Biopharma Inc.
Grant date
Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K38/08, A61K38/10, A61K38/17, A61K38/1709